Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...

Rather than merely masking pain signals like conventional analgesics, this new medication directly tackles the root cause of ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

The company will present these findings and data from previous studies at the upcoming Pain Therapeutics Summit. The company is preparing to submit an Investigational New Drug (IND) application by ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) stock is trading higher on Monday after the company released new preclinical ...